Pertuzumab%2C Trastuzumab%2C And Hyaluronidase Zzxf + Anthracycline Interaction
Majorinteraction on record
Description
7 DRUG INTERACTIONS Patients who receive anthracycline after stopping PHESGO may be at increased risk of cardiac dysfunction because of PHESGO's long washout period [see Clinical Pharmacology (12.3) ] . If possible, avoid anthracycline-based therapy for up to 7 months after stopping PHESGO. If anthracyclines are used, carefully monitor the patient's cardiac function.
Source: FDA drug label - pertuzumab, trastuzumab, and hyaluronidase-zzxf